pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Hemady
drug
save

dexamethasone

Marketedupdated 6mo ago
by Fera Pharmaceuticals LLC
Approved
community read0 votes

indications

investigational
Multiple SclerosisIBD (Crohn's + UC)Rheumatoid ArthritisPsoriasisLupusAsthma

all catalysts(10)

phase 0 trial completion · 1
Apr 30, 2026
phase 0 trial completion
7mo ago
Yangzhou No.1 People's Hospital — dexamethasone (Phase 0 Trial Completion)
dexamethasone
→
phase 2 completion · 7
Apr 25, 2026
phase 2 completion
7mo ago
Nizam's Institute of Medical Sciences — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 25, 2026
phase 2 completion
7mo ago
Assiut University — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 27, 2026
phase 2 completion
7mo ago
BC Children's Hospital Research Institute — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 28, 2026
phase 2 completion
7mo ago
West China Hospital of Stomatology — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
7mo ago
Buddhachinaraj Hospital — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
7mo ago
Dalian Municipal Central Hospital — dexamethasone (Phase II Trial Completion)
dexamethasone
→
Apr 30, 2026
phase 2 completion
7mo ago
ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini — dexamethasone (Phase II Trial Completion)
dexamethasone
→
phase 2 initiation · 1
Apr 25, 2026
phase 2 initiation
7mo ago
Gaziantep City Hospital — dexamethasone (Phase II Trial Initiation)
dexamethasone
→
phase iv trial initiation · 1
Apr 27, 2026
phase iv trial initiation
7mo ago
Jawaharlal Nehru Medical College — dexamethasone (Phase IV Trial Initiation)
dexamethasone
→
view all 10 catalysts →

Trials studying dexamethasone

  • phase3To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myelomanot yet recruitingn=750
  • phase2Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)active not recruitingn=220
  • phase3Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myelomaactive not recruitingn=494
  • phase3A Study in Participants With Relapsed or Refractory Multiple Myeloma for QLS4131not yet recruitingn=300
  • phase4Lipiflow Treatment Alone vs. Lipiflow + Dextenza Treatment for Dry Eye Diseasecompletedn=20
  • phase3A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)recruitingn=770
  • phase3A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)active not recruitingn=260
  • phase2Cevostamab in Combination With Pomalidomide and Dexamethasone After BCMA- Targeting CAR T-Cell Therapy in Participants With Previously Treated Multiple Myelomarecruitingn=45

Patent cliff

source: FDA Orange Book
first barrier falls
Dec 18, 2037
~11.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

  • Dec 18, 2037formulationUS 10537585
  • Dec 18, 2037formulationUS 11304961

FDA exclusivities (1)

  • Oct 3, 2026ODE-271Orphan Drug (7y)

News(0)

no news has mentioned this drug yet

brand
Hemady
generic
dexamethasone [INN]
indication
Multiple Myeloma (Kahler Disease)
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?